Morphic Holding Inc

Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Eli Lilly

Eli Lilly And Co (NYSE:LLY) announced earlier today it will acquire Morphic Holding (NASDAQ:MORF) for $3.2 billion in cash, expanding its inflammatory bowel disease (IBD) drug portfolio.

More Records Highs for Eli Lilly Stock After Buyout

Eli Lilly (LLY) agreed to buy biopharmaceutical firm Morphic (MORF) at a significant premium, sending shares of Morphic skyrocketing Monday.

Eli Lilly Buys Morphic for $3.2B

Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced Monday, a transaction that includes an experimental medication for inflammatory bowel disease and treatments for other chronic diseases.

Eli Lilly Buys Bowel Disease Drug Developer Morphic In $3.2 Billion Deal

Eli Lilly and Co (NYSE:LLY) has struck a deal to acquire Morphic Holding Inc (NASDAQ:MORF), a maker of inflammatory bowel disease (IBD) drugs, for approximately $3.2 billion. On a per-share basis the deal is priced at $57, to be paid in cash.

Eli Lilly acquires IBD drug developer Morphic in $3.2bn deal

MONSEY, N.Y., July 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Morphic Holding, Inc. (Nasdaq: MORF) (“Morphic”) to Eli Lilly and Company (“Eli Lilly”) for $57.00 per share in cash in a tender offer.

MORF Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Morphic Holding to Eli Lilly

Alibaba

Nasdaq flat, but Alibaba shares dip 1.17% pre-market as AI progress showcased at Shanghai conference.

Nasdaq Index, Dow Jones, S&P 500 News: Morphic Holding Shares Surge Over 75%; Alibaba Group Stumbles

Monday, Eli Lilly And Co LLY agreed to acquire Morphic Holding Inc MORF for $57 per share in cash, an aggregate of approximately $3.2 billion.

Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B

Eli Lilly said Monday it would pay $3.2 billion to acquire an innovator in oral treatments for chronic bowel diseases.

Eli Lilly Snaps Up Morphic At 79% Premium

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Morphic Holding, Inc. (NASDAQ: MORF) to Eli Lilly and Company for $57.00 per share in cash is fair to Morphic shareholders. Halper Sadeh encourages Morphic shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Morphi.

MORF Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Morphic Holding, Inc. Is Fair to Shareholders

Eli Lilly agrees to pay $57 a share for Morphic, or a 79% premium to the stock's closing price of $31.84 on Friday.

Eli Lilly to Buy Morphic for $3.2 Billion. Morphic Stock Surges 78%.

Shares of Morphic Holding Inc. MORF, +0.03% rocketed 76% in premarket trading Monday, after the biopharmaceutical company announced an agreement to be acquired by Eli Lilly & Co. LLY, +1.83% in a cash deal valued at about $3.2 billion. Lilly's stock LLY, +1.83% tacked on 0.2% ahead of the open.

Morphic's stock rockets after $3.2 billion buyout deal with Eli Lilly

Eli Lilly will acquire Morphic Holding for $3.2 billion, the companies said on Monday.

Eli Lilly to acquire Morphic Holding for $3.2 billion

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass. , July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.

Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Johnson Fistel, is investigating potential securities claims against Morphic Holding, Inc. (NASDAQ:MORF) on behalf of stockholders. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

MORF NEWS: Johnson Fistel Continues Investigation on Behalf of Morphic Holding Shareholders

WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:30 AM ET.

Morphic to Participate in Jefferies Global Healthcare Conference

MORF ends 1Q24 with $659 million, cash into 2H27; phase 2b study of MORF-057 in UC continues on target; anticipate GARNET phase 2 in Crohn's to begin 2Q

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024

Morphic (MORF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Morphic (MORF) a New Buy Stock

LOS ANGELES, CA / ACCESSWIRE / April 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm

MILWAUKEE , April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Morphic (NASDAQ: MORF). The investigation results from inaccurate statements Morphic may have made regarding its business operations and prospects.

Ademi LLP Investigates Claims of Securities Fraud against Morphic Holding, Inc.

NEW YORK--(BUSINESS WIRE)---- $MORF #classaction--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Morphic Holding, Inc. (“Morphic” or “the Company”) (NASDAQ: MORF). Investors who purchased Morphic securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/morf. The investigation concerns whether Morphic has violated federal securities laws. Investigation Details: On September.

Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory Diseases Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory Diseases

Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation at investor conferences during the month of March.

News for Morphic Holding Inc Stock (MORF)